Subscribe to RSS
DOI: 10.1055/s-2005-917076
Development of New Methodologies for Entry to Targets of Therapeutic Interest
Publication History
Publication Date:
05 October 2005 (online)
![](https://www.thieme-connect.de/media/synlett/200517/lookinside/thumbnails/10.1055-s-2005-917076-1.jpg)
Abstract
This Account provides an overview of strategies that have been reported from our laboratories for the synthesis of targets of therapeutic interest, namely carbohydrates, and prodrugs for the treatment of melanoma. These programmes have involved the development of new synthetic methodologies including the regio- and stereoselective synthesis of specific carbohydrate isomers, and new protecting group methodologies. This review provides an insight into the progress of these research themes, and suggests some applications for the targets that are currently being explored.
-
1 Carbohydrate Targets
-
1.1 The Development of Regioselective Protection and Glycosidation Protocols
-
1.2 The Stereoselective Synthesis of α-Linked GlcNAc and
β-Linked ManNAc Residues -
1.3 Development of Methodology for the Synthesis of Multivalent Carbohydrate Arrays
-
1.4 Development of Methodology for the Synthesis of Glycosidase Inhibitors
-
2 The Design and Analysis of Novel Prodrugs for the Treatment of Melanoma
-
3 Development of Tyrosinase Labile Protecting Groups for Amines
Key words
carbohydrates - prodrugs - regioselective - stereoselective - melanoma
- For example see:
-
1a
Koeller KM.Wong C.-H. Nature Biotechnol. 2000, 18: 835 -
1b
Bertozzi CR.Kiessling LL. Science 2001, 291: 2357 -
1c
Davis BG. Chem. Rev. 2002, 102: 579 -
1d
Dwek RA.Butters TD. Chem. Rev. 2002, 102: 283 -
1e
Werz DB.Seeberger PH. Chem.-Eur. J. 2005, 11: 3194 - 2 For a recent overview of carbohydrate protecting group strategies see:
Robertson J.Stafford PM. In Carbohydrates: Best Synthetic Methods Academic Press; London: 2003. Chap. 2. - For example see:
-
3a
Haines AH. Adv. Carbohydr. Chem. Biochem. 1976, 33: 11 -
3b
Haines AH. Adv. Carbohydr. Chem. Biochem. 1981, 39: 13 - For example see:
-
4a
Yu B.Yang ZY.Cao HZ. Curr. Org. Chem. 2005, 9: 179 -
4b
Baeschlin DK.Green LG.Hahn MG.Hinzen B.Ince SJ.Ley SV. Tetrahedron: Asymmetry 2000, 11: 173 -
4c
Grice P.Ley SV.Osborn HMI.Priepke HWM.Warriner SL. Chem.-Eur. J. 1997, 3: 431 -
4d
Wong CH.Mong KKT. Angew. Chem. Int. Ed. 2002, 41: 4087 - For example see:
-
5a
Bashir NB.Phythian SJ.Reason AJ.Roberts SM. J. Chem. Soc., Perkin Trans. 1 1995, 2203 -
5b
Chinn MJ.Iacazio G.Spackman DG.Turner NJ.Roberts SM. J. Chem. Soc., Perkin Trans. 1 1992, 661 -
5c
Iacazio G.Roberts SM. J. Chem. Soc., Perkin Trans. 1 1993, 1099 -
5d
Panza L.Brasca S.Riva S.Russo G. Tetrahedron: Asymmetry 1993, 4: 931 -
6a
Gridley JJ.Hacking AJ.Osborn HMI.Spackman DG. Synlett 1997, 1397 -
6b
Gridley JJ.Hacking AJ.Osborn HMI.Spackman DG. Tetrahedron 1998, 54: 14925 -
7a
Eby R.Schuerch C. Carbohydr. Res. 1982, 100: C41 -
7b
Eby R.Webster KT.Schuerch C. Carbohydr. Res. 1984, 129: 111 -
7c
Avela E.Melander B.Holmbom B. Acta Acad. Abstr., Ser. B 1971, 14: 31 -
8a
Osborn HMI.Brome VA.Harwood LM.Suthers WG. Carbohydr. Res. 2001, 332: 157 -
8b
Gridley JJ.Osborn HMI.Suthers WG. Tetrahedron Lett. 1999, 40: 6991 -
9a
Garegg PJ.Maloisel J.-L.Oscarson S. Synthesis 1995, 409 -
9b
Garegg PJ.Olsson L.Oscarson S. Bioorg. Med. Chem. 1996, 4: 1867 -
9c
Kaji E.Harta N. Tetrahedron Lett. 2000, 41: 53 - 10
Evans PG.Osborn HMI.Suthers WG. Tetrahedron Lett. 2002, 43: 7855 - 11 For a useful review see:
Kaji E.Lichtenthaler FW. Trends Glycosci. Glycotechnol. 1993, 5: 121 - 12
Gridley JJ.Osborn HMI. J. Chem. Soc., Perkin Trans. 1 2000, 1471 - For recent examples see:
-
13a
Crich D.Li WJ.Li HM. J. Am. Chem. Soc. 2004, 126: 15081 -
13b
Crich D.Banerjee A.Yao QJ. J. Am. Chem. Soc. 2004, 126: 14930 -
14a
Drew MGB.Ennis SC.Gridley JJ.Osborn HMI.Spackman DG. Tetrahedron 2001, 57: 7919 -
14b
Ennis SC.Gridley JJ.Osborn HMI.Spackman DG. Synlett 2000, 1593 -
15a
Mulvey G.Kitov PI.Marcato P.Bundle DR.Armstrong GD. Biochimie 2001, 83: 841 -
15b
Zopf D.Roth S. Lancet 1996, 347: 1017 -
16a
Mouricout M.Petit JM.Carias JR.Julien R. Infect. Immun. 1990, 58: 98 -
16b
Griemel P.Spreitz J.Stutz AE.Wrodnigg TM. Curr. Top. Med. Chem. 2003, 3: 513 -
17a
Ofek I.Sharon N. Curr. Top. Microbiol. Immunol. 1990, 151: 91 -
17b
Ofek I.Mirelman D.Sharon N. Nature (London) 1977, 265: 623 -
17c
Ofek I.Beachey EH. Infect. Immun. 1978, 22: 247 - For example see:
-
18a
Ashton PR.Hounsell EF.Jayaraman N.Nilsen TM.Spencer N.Stoddart JF.Young M. J. Org. Chem. 1998, 63: 3429 -
18b
Corbell JB.Lundquist JJ.Toone EJ. Tetrahedron: Asymmetry 2000, 11: 95 -
18c
Page D.Roy R. Bioconjugate Chem. 1997, 8: 10 - 19
Firon N.Ofek I.Sharon N. Infect. Immun. 1984, 43: 1088 - 20
Madiyalakan R.Chowdhary MS.Rana SS.Matta KL. Carbohydr. Res. 1986, 152: 183 - 21
Suwasono S.Rastall RA. Biotech. Lett. 1996, 18: 851 - For relevant examples see:
-
22a
MacLeod JM. Carbohydr. Res. 1979, 75: 71 -
22b
Gaucher SP.Pedersen SF.Leary JA. J. Org. Chem. 1999, 64: 4012 - 23
Hayes W.Romagnoli B.Harwood LM.Philp D.Price DW.Smith M. Tetrahedron Lett. 2003, 44: 37 -
24a
Hayes W.Osborn HMI.Osborne SD.Rastall RA.Romagnoli B. Tetrahedron Lett. 2003, 44: 37 -
24b
Hayes W.Osborn HMI.Osborne SD.Rastall RA.Romagnoli B. Tetrahedron 2003, 59: 7983 - For example see:
-
25a
Lillelund VH.Jensen HH.Liang XF.Bols M. Chem. Rev. 2002, 102: 515 -
25b
Asano N.Nash RJ.Molyneux RJ.Fleet GWJ. Tetrahedron: Asymmetry 2000, 11: 1645 -
25c
El Ashry ESH.Rashed N.Shobier AHS. Pharmazie 2000, 55: 251 - For example see:
-
26a
Sinnott ML. Chem. Rev. 1990, 90: 1171 -
26b
Wong C.-H.Halcomb RL.Ichikawa Y.Kajimoto T. Angew. Chem., Int. Ed. Engl. 1995, 34: 521 -
26c
Legler G. Adv. Carbohydr. Chem. Biochem. 1990, 48: 319 - 27
Jordan AM.Osborn HMI.Stafford PM.Tzortzis G.Rastall RA. J. Carb. Chem. 2003, 22: 705 - 28 For a recent review of the Ferrier reaction see:
Ferrier RJ. Top. Curr. Chem. 2001, 215: 153 - For example see:
-
29a
Vogel P. Chimia 2001, 55: 359 -
29b
Weatherman RV.Kiessling LL. J. Org. Chem. 1996, 61: 534 -
29c
Weatherman RV.Mortell KH.Chevenak M.Kiessling LL.Toone EJ. Biochemistry 1996, 35: 3619 - 30
Gemmell N.Osborn HMI.Meo P. Org. Lett. 2003, 5: 1649 - 31
Brimble MA.Brenstrum TJ. J. Chem. Soc., Perkin Trans. 1 2001, 1612 - 32
Clark SM.Osborn HMI. Tetrahedron: Asymmetry 2004, 15: 3643 -
33a
Herreros E.Almela MJ.Lozano S.De Las Heras FG.Gargallo-Viola D. Antimicrob. Agents Chemother. 2001, 45: 3132 -
33b
Okazaki S.Shirai N.Sato Y. J. Org. Chem. 1990, 55: 334 - 34
Osborn HMI.Evans PG.Gemmell N.Osborne SD. J. Pharm. Pharmacol. 2004, 56: 691 - 35 For a recent review see:
Rooseboom M.Commandeur JNM.Vermeulen NPE. Pharmacol. Rev. 2004, 56: 53 - For recent reviews see
-
36a
Rooseboom M.Commandeur JNM.Vermeulen NPE. Pharmacol. Rev. 2004, 56: 53 -
36b
Tietze LF.Feverstein T. Curr. Pharm. Des. 2003, 9: 2155 -
36c
Goodwin DA.Meares CF. Biotechnol. Adv. 2001, 19: 435 -
36d
Syrigos KN.Epenetos AA. Anticancer Res. 1999, 19: 605 -
37a
Ito Y.Jimbow K. Cancer Res. 1987, 47: 3278 -
37b
Morrison ME.Yagi MJ.Cohen G. Proc. Natl. Acad. Sci. U.S.A. 1985, 82: 2960 -
37c
Riley PA. Pigment Cell Res. 2003, 16: 548 -
38a
Jordan AM.Khan TH.Osborn HMI.Photiou A.Riley PA. Bioorg. Med. Chem. 1999, 7: 1775 -
38b
Jordan AM.Khan TH.Malkin H.Osborn HMI.Photiou A.Riley PA. Bioorg. Med. Chem. 2001, 9: 1549 -
38c
Jordan AM.Khan TH.Malkin H.Osborn HMI. Bioorg. Med. Chem. 2002, 10: 2625 - For details of melanin biosynthesis see:
-
39a
Riley PA. Eur. J. Cancer 1991, 27: 1172 -
39b
Jimbow K.Iwashina T.Alena F.Yamada K.Panchovich J.Umemura T. J. Invest. Dermatol. 1993, 100: 231 -
39c
Pawelek J.Korner A.Bergstrom A.Bologna J. Nature (London) 1980, 286: 617 -
39d
Land EJ.Ramsden CA.Riley PA. Methods Enzymol. 2004, 378: 88 -
40a
Schoot-Uiterkamp AJM.Mason HS. Proc. Natl. Acad. Sci. U. S. A. 1973, 70: 993 -
40b
Nishioka K. Eur. J. Biochem. 1978, 85: 137 - 41
Osborn HMI.Williams NAO. Org. Lett. 2004, 6: 3111 - For recent reviews see:
-
42a
Kadereit DK.Waldmann H. Chem. Rev. 2001, 101: 3367 -
42b
Kadereit D.Waldmann H. Monatsh. Chem. 2000, 131: 571 - 43 For a recent review see:
Land EJ.Ramsden CA.Riley PA. Acc. Chem. Res. 2003, 36: 300